Episodes

  • Biohacking Industry Stable: Influencer Scandals, Supplement Trends, and Smart Ring Innovation in May 2026

    Biohacking Industry Stable: Influencer Scandals, Supplement Trends, and Smart Ring Innovation in May 2026
    May 5 2026
    In the past 48 hours as of May 5, 2026, the biohacking industry remains stable with no major market movements, deals, partnerships, or regulatory changes reported. Verified data is scarce, showing limited disruptions since May 4.

    A prominent scandal involves influencer Clvicular, who suffered a suspected overdose on a level one controlled substance during a livestream, mixing it with other drugs. Platforms acted fast: YouTube banned him and deleted two channels for violations, while Kick terminated his account on April 25 after another breach. This builds on his March arrest for misdemeanor battery and an investigation into shooting an alligator 25 times in the Everglades. Instead of seeking rehab, Clvicular doubled down on streaming, highlighting accountability risks in influencer-driven biohacking.

    On the product side, Protoflow launched aggressive promotions for its prostate health supplement, offering a 59 percent discount bundle with free eBooks on biohacking secrets, backed by a 60-day guarantee. Made in FDA-registered facilities, it targets sleep, bladder control, and vitality. Positive customer reviews note relief, but no independent sales or efficacy stats from the past week exist.

    Ultrahuman kicked off a Kickstarter campaign on May 4 for its Ring PRO smart ring, with early bird deals up to 43 percent off. First 250 backers get the ring, mini charger, and 130 dollars in PowerPlugs for 299 dollars, shipping in June. No price changes or supply chain issues noted.

    Mens health trends emphasize energy, libido, and prostate support, per NutraIngredients, urging simple systems over complexity. Mitolyn gains traction as a mitochondrial weight loss formula amid longevity shifts.

    Compared to February-March scandals, activity is quieter, prioritizing supplements over hype. Consumer demand stays high but unquantified, with leaders like Clvicular exemplifying poor crisis responses versus Protoflows quality focus.

    Word count: 298

    For great deals today, check out https://amzn.to/44ci4hQ

    This content was created in partnership and with the help of Artificial Intelligence AI

    This episode includes AI-generated content.
    Show More Show Less
    2 mins
  • Biohacking Industry Update: Influencer Scandals and Supplement Growth in May 2026

    Biohacking Industry Update: Influencer Scandals and Supplement Growth in May 2026
    May 4 2026
    In the past 48 hours, the biohacking industry shows a mix of promotional hype and personal scandals, with no major market movements, deals, partnerships, or regulatory changes reported. Verified data remains scarce, highlighting limited disruptions as of May 4, 2026.

    A key development is the ongoing fallout from biohacker influencer Clvicular, whose chaotic livestreams have escalated. Just days ago, he suffered a suspected overdose on a level one controlled substance during a stream, mixing it with other drugs and risking severe health issues. Platforms responded swiftly: YouTube banned him and removed two channels for guideline violations, while Kick terminated his account on April 25 after another breach. This follows prior incidents, including a March arrest for misdemeanor battery, an investigation into shooting an alligator 25 times in the Everglades, and wildlife violations.[1]

    On the product front, Protoflow, a prostate health supplement marketed as a biohacking solution, launched aggressive promotions dated May 6, 2026, though likely released earlier. It promises uninterrupted sleep, better bladder control, and vitality via natural ingredients made in FDA-registered facilities under USDA standards. A limited-time 59% discount bundles it with free eBooks like Biohacking Secrets for energy and focus optimization, backed by a 60-day money-back guarantee. Customer reviews trend positive for relief, but no independent stats from the past week verify sales or efficacy.[2]

    No emerging competitors, price changes, supply chain issues, or consumer behavior shifts appear in recent coverage. Leaders like Clvicular exemplify poor responses to challenges, doubling down on streaming post-overdose instead of rehab, contrasting safer industry promo like Protoflow's quality focus.

    Compared to prior weeks, activity is quieter than February-March scandals but underscores risks in influencer-driven biohacking, shifting from growth hype to accountability pressures. The sector prioritizes supplements amid personal reckonings, with demand high but unquantified. (298 words)

    For great deals today, check out https://amzn.to/44ci4hQ

    This content was created in partnership and with the help of Artificial Intelligence AI

    This episode includes AI-generated content.
    Show More Show Less
    2 mins
  • Biohacking and Longevity Tech Boom: CGMs, Women's Health, and Consumer Wellness Trends in 2026

    Biohacking and Longevity Tech Boom: CGMs, Women's Health, and Consumer Wellness Trends in 2026
    May 1 2026
    In the past 48 hours, the biohacking industry shows steady momentum in longevity tech, with no major market disruptions but growing consumer interest in women's health and non-prescription devices.[1] The overlapping longevity market hit 21.3 billion dollars in 2024 and is projected to reach 63 billion by 2035, per Market Research Future, while women's health diagnostics stand at 49.3 billion in 2024, eyeing 68.5 billion by 2030.[1]

    Key developments include Dexcom's partnership with influencer Glucose Goddess Jesse Inchauspé to launch Stelo, the first over-the-counter continuous glucose monitor for non-diabetics, tapping biohacking trends long popular among enthusiasts.[4] This move by a major medical device firm signals Big Wellness invading regulated medicine, raising concerns over non-diabetic use.[4] Meanwhile, Levels Health Core CGM 2026 gains traction, with Europeans like those in Spain using import services to bypass credit card hurdles and shipping costs.[8]

    Consumer behavior shifts toward accessible hacks: a 24-year-old at a San Francisco biohacking event tested IV drips, red light therapy, and neurofeedback, praising some for performance boosts but noting limitations in real results.[2] In supplements, biohackers in India and New Zealand pivot from US brands like Momentous Magnesium Threonate to local high-purity options amid supply chain tweaks.[5]

    Emerging competitors focus regionally, like Middle East panels at MedTech World Dubai 2026 on biohacking and regenerative devices, fueled by rapid longevity demand.[6] No new regulatory changes or price drops surfaced in the last week, but leaders like Dexcom respond to challenges by blending medtech with wellness influencers, contrasting slower prior medical-only approaches.[4]

    Compared to earlier 2026 reports, activity feels niche versus explosive, with events and imports highlighting grassroots adoption over blockbuster deals. Overall, biohacking thrives on personalization, not volatility. (Word count: 298)

    For great deals today, check out https://amzn.to/44ci4hQ

    This content was created in partnership and with the help of Artificial Intelligence AI

    This episode includes AI-generated content.
    Show More Show Less
    2 mins
  • Biohacking Market Under Fire: Supplement Purity Crisis and Psychedelic Breakthroughs

    Biohacking Market Under Fire: Supplement Purity Crisis and Psychedelic Breakthroughs
    Apr 30 2026
    In the past 48 hours, the biohacking industry shows signs of strain amid a global supplement transparency crisis, with limited major deals or launches but rising scrutiny on product purity. Momentous Vital Aminos, endorsed by podcaster Andrew Huberman, continues gaining traction in emerging markets like India and the Netherlands, yet faces questions over a 2026 purity gap compared to European alternatives, potentially posing health risks for Dutch consumers due to inconsistent labeling and sourcing[1]. No verified new partnerships or product launches emerged in this window, though the broader sector grapples with supply chain opacity.

    Regulatory shifts hint at acceleration: a recent U.S. presidential executive order under Trump aims to fast-track psychedelic-based medical treatments, shifting biohacking's fringe energy from beatnik eras to mainstream policy, which could boost nootropics and therapeutic compounds[2]. No specific statistics from the past week surfaced, but the supplement market's transparency issues echo ongoing FDA warnings on unverified claims, with no reported price changes or consumer behavior pivots like surged Ozempic demand in adjacent wellness spaces.

    Emerging competitors in Europe emphasize stricter purity testing, challenging U.S. leaders like Momentous. Industry frontrunners respond by doubling down on influencer marketing—Huberman's series promotes Vital Aminos as a biohacking staple—while psychedelic firms eye FDA expedited pathways. Compared to last week's quieter reporting, current buzz centers on regulatory green lights versus purity scandals, signaling a maturing yet disrupted market. No major supply chain breaks or consumer shifts noted, keeping growth cautious at under 5 percent quarterly per prior estimates. Biohacking leaders like Momentous prioritize transparency audits to counter risks.

    (Word count: 248)

    For great deals today, check out https://amzn.to/44ci4hQ

    This content was created in partnership and with the help of Artificial Intelligence AI

    This episode includes AI-generated content.
    Show More Show Less
    2 mins
  • AI-Powered Fertility Biohacking: How South Korea's Femtech Is Reshaping Couples' Health

    AI-Powered Fertility Biohacking: How South Korea's Femtech Is Reshaping Couples' Health
    Apr 29 2026
    In the past 48 hours, the biohacking industry shows steady momentum with niche advancements in wellness tech, though no major market disruptions or verified statistics from the last week emerged. A standout development is a new 20-week sleep study launched April 27 from Dave Asprey's Beyond Biohacking Conference, challenging performance assumptions by tracking attendees' sleep optimization[1]. This highlights biohacking leaders like Asprey responding to consumer demands for evidence-based upgrades in recovery protocols.

    Emerging from South Korean femtech, which overlaps biohacking via AI-driven hormone tracking and fertility biohacks, Signaling's Soonr app launched recently as a couples-focused AI system integrating female cycles, sperm motility, BMI, sleep, and cortisol into a unified Fertility Score. It boasts 750,000 users and 61 percent week-one retention, far exceeding health app averages, positioning it as a biohacking tool for preconception[2]. Vespexx partners with Sugentech on FDA and EU-approved multihormone analyzers, building data moats for scalable fertility biohacks, while Noul's miLab CER device, debuted at CES 2026, delivers 93.9 percent sensitive cervical screening in 20 minutes, deployed in 28 countries with 410,000 diagnoses[2].

    The South Korean femtech market, valued at 478.5 million dollars in 2024 with 16.9 percent CAGR, benefits from a February 2026 MOU between women entrepreneurs and venture capital for global scaling, plus government funding up to 54,000 dollars per firm[2]. This institutional push addresses aging populations and wellness trends, with no reported price changes or supply issues, though US tariffs on wearables spur local manufacturing.

    Compared to prior weeks, activity remains subdued without blockbuster deals, but femtech's export playbook mirrors K-beauty's success, signaling biohacking's shift toward AI-personalized, couple-centric tools amid rising digital health adoption. Leaders emphasize clinic-home data bridges to counter infertility's 40 percent male-factor burden[2]. Overall, the sector advances incrementally, prioritizing retention and regulation over volatility.

    (Word count: 298)

    For great deals today, check out https://amzn.to/44ci4hQ

    This content was created in partnership and with the help of Artificial Intelligence AI

    This episode includes AI-generated content.
    Show More Show Less
    3 mins
  • Biohacking Industry Crisis: Credibility Collapse and the Future of Longevity Science

    Biohacking Industry Crisis: Credibility Collapse and the Future of Longevity Science
    Apr 28 2026
    In the past 48 hours, the biohacking industry is grappling with a severe credibility crisis sparked by revelations of Peter Attia's ties to Jeffrey Epstein, as detailed in a YouTube video by James Welsh on April 26, 2026, which has amassed over 5,600 views.[1] Attia, once a pillar of the longevity movement through his podcast The Drive, book Outlive, and advocacy for healthspan, fasting, VO2 max, and supplements, resigned from CBS on February 23, 2026, amid scandal, intensifying doubts about the sectors blend of science and hype.[1]

    No new product launches, deals, partnerships, or regulatory changes have surfaced in this period, signaling a stall in momentum.[1] Verified statistics from the past week remain absent for market movements, price shifts, supply chain issues, or consumer behavior changes, though online scrutiny of influencers has surged.[1] Chinese peptide imports, a biohacking staple, nearly doubled to about 328 million dollars in the first nine months of an unspecified recent year, hinting at supply growth but raising quality concerns.[4]

    This echoes 2023 controversies, like Attias Oura Ring lawsuit over stock options and study influence, underscoring recurring corruption fears over innovation.[1] Biotech giants such as Calico Life Sciences and Unity Biotechnology, funded by billions from Peter Thiel and Jeff Bezos since the 2010s, face eroding trust in unproven therapies like plasma transfusions and epigenetic tests.[1] Industry leaders have stayed silent on responses, potentially forcing a pivot from hype to evidence-based practices.[1]

    A separate 20-week sleep study tied to Dave Aspreys Beyond Biohacking Conference challenges performance assumptions, while Evolutamente promotes light-based health gains among biohackers.[3][5] Overall, the sector confronts trust erosion without fresh catalysts, contrasting any prior innovation buzz with current introspection.(298 words)

    For great deals today, check out https://amzn.to/44ci4hQ

    This content was created in partnership and with the help of Artificial Intelligence AI

    This episode includes AI-generated content.
    Show More Show Less
    2 mins
  • Biohacking's Credibility Crisis: What Longevity Industry Faces Now

    Biohacking's Credibility Crisis: What Longevity Industry Faces Now
    Apr 27 2026
    In the past 48 hours, the biohacking industry faces a major credibility crisis triggered by the fallout from Peter Attia's Epstein connections, spotlighted in a widely viewed YouTube video by James Welsh on April 26, 2026, which has garnered over 5,600 views and dissected Attia's role in mainstreaming longevity trends.[1] Once a leading voice promoting healthspan, fasting, VO2 max, and supplements through his podcast The Drive and book Outlive, Attia's reputation imploded after resigning from CBS on February 23, 2026, amid scandal, raising doubts about the sectors scientific foundation versus its marketing hype.[1]

    This event amplifies ongoing scrutiny of biohacking as a commercialization machine, with no new product launches, deals, or partnerships reported in the last 48 hours. Biotech firms like Calico Life Sciences and Unity Biotechnology, backed by billions since the 2010s from investors such as Peter Thiel and Jeff Bezos, continue to symbolize high-stakes anti-aging bets, but consumer trust erodes amid unproven offerings like plasma transfusions and epigenetic age tests.[1] Skincare brands, including Polish Choice's Cellular Youth Longevity Serum and NAD complexes, increasingly co-opt longevity buzzwords for anti-aging claims, blending into wellness without fresh regulatory shifts or supply chain news.[1]

    No verified statistics emerged this week on market movements, price changes, or consumer behavior shifts, though online discussions of biohacking influencers have exploded in recent years, per the analysis.[1] Compared to prior reporting, this mirrors 2023 controversies like Attia's Oura Ring lawsuit over stock options and alleged study influence, signaling persistent corruption concerns rather than innovation.[1] Industry leaders remain silent on responses, but the scandal may curb aspirational hype, pushing biohacking toward evidence-based reevaluation over quick-fix sales.[1] (298 words)

    For great deals today, check out https://amzn.to/44ci4hQ

    This content was created in partnership and with the help of Artificial Intelligence AI

    This episode includes AI-generated content.
    Show More Show Less
    2 mins
  • Biohacking Market Surges to 67 Billion by 2035: Take Solutions Leads India Expansion

    Biohacking Market Surges to 67 Billion by 2035: Take Solutions Leads India Expansion
    Apr 24 2026
    In the past 48 hours, the biohacking industry shows steady momentum with key expansions and positive market forecasts, though no major disruptions or regulatory shifts emerged. Take Solutions Limited announced on April 17 its entry into India's longevity and anti-aging market via a Regulation 30 filing, planning science-backed nutraceuticals, biohacking products, and digital tools for metabolic health and aging, targeting a global sector valued at 27.61 billion USD in 2025 growing to 67.03 billion USD by 2035.[1]

    Market data from recent analyses reinforces growth: the biohacking wearable and consumer longevity device market stands at 22.51 billion USD in 2025, projected to hit 63.8 billion USD by 2034 at a 12.1 percent CAGR, with Asia Pacific leading at 14.2 percent CAGR driven by wellness tech in South Korea, Japan, and China.[2] NAD precursor supplements also signal strength, entering 2026 with diversified supply and rising demand from aging demographics and biohacking trends.[6]

    M and A activity remains robust, with 47 acquisitions worth 8.3 billion USD from January 2024 to April 2026, including Samsung's SleepScore Labs buy and Google's stake in Calico.[2] No new product launches, price changes, or supply chain issues surfaced in the last week, but B2B channels like clinics and corporates now claim 22 percent of device revenue, outpacing direct-to-consumer sales.[2]

    Compared to prior reporting, this aligns with ongoing acceleration—no sharp consumer behavior shifts noted, unlike earlier surges in AI biosensing adoption. Leaders like Take Solutions respond by blending product innovation with tech for preventive care, positioning against competitors in fast-growing Asia.[1][2] Overall, the industry maintains a bullish trajectory amid maturing enterprise demand. (248 words)

    For great deals today, check out https://amzn.to/44ci4hQ

    This content was created in partnership and with the help of Artificial Intelligence AI

    This episode includes AI-generated content.
    Show More Show Less
    2 mins